Sino Biopharm and MediTrust Health Partner to Advance Drug-Insurance Integration Model

Sino Biopharmaceutical Limited and Shanghai MediTrust Health have signed a strategic cooperation agreement during the 8th China International Import Expo (CIIE) to jointly develop a new model integrating innovative drugs with commercial insurance. The partnership aims to expand early access to high-quality, affordable treatments by combining pharmaceutical innovation with insurance-based affordability mechanisms.

Collaboration Strengthens Access to Affordable Medicines

The agreement focuses on aligning innovative drug development with commercial insurance pathways, enabling more patients to benefit from breakthrough therapies earlier. Leaders from both organizations, including Sino Biopharm’s Executive Director Tse Hsin and MediTrust Health President Wang Rundong, emphasized the collaboration’s potential to improve patient affordability and reduce strain on public healthcare resources.

Strategic Value for China’s Evolving Healthcare Landscape

Sino Biopharm, which generates about RMB 30 billion in annual revenue and ranks 38th globally among pharmaceutical companies, highlighted that commercial insurance is becoming a vital channel for innovative therapies. The partnership is expected to support long-term R&D investment, accelerate market access for new medicines, and contribute to a more sustainable healthcare ecosystem in China.